Page 207 - HIV/AIDS Guidelines

Table 15c. Drug Interactions between Nucleoside Reverse Transriptase Inhibitors and Other Drugs
(Including Antiretroviral Agents) (Page 2 of 2)

Concomitant Effect on NRTI or Concomitant Dosage Recommendations and Clinical
Drug Class/ NRTI
Name Drug Concentrations Comments

TDF TDF AUC ↑ 22%, C max ↑ 24%, and Clinical significance unknown. Monitor for TDF toxicity.
DRV/r
C min ↑ 37%
LPV/r TDF LPV/r AUC ↓ 15% Clinical significance unknown. Monitor for TDF toxicity.
TDF AUC ↑ 34%

ABC ABC AUC ↓ 35%–44% Appropriate doses for this combination have not been
established.

ddI ddI-EC AUC ↔ and C min ↓ 34% Separate doses by at least 2 hours.
TPV/r ↔
TPV/r TDF TDF AUC ↔ No dosage adjustment necessary.
TPV/r AUC ↓ 9%–18% and
C min ↓ 12%–21%

ZDV ZDV AUC ↓ 35% Appropriate doses for this combination have not been
TPV/r AUC ↓ 31%–43% established.

Key to Abbreviations: 3TC = lamivudine, ABC = abacavir, ART = antiretroviral, ATV = atazanavir, ATV/r = atazanavir/ritonavir, AUC = area
under the curve, C max = maximum plasma concentration, C min = minimum plasma concentration, d4T = stavudine, ddI = didanosine,
DRV/r = darunavir/ritonavir, EC = enteric coated, LPV/r = lopinavir/ritonavir, NRTI = nucleoside reverse transcriptase inhibitor, PI = protease
inhibitor, PK = pharmacokinetic, RAL = raltegravir, TDF = tenofovir, TPV/r = tipranavir/ritonavir, ZDV = zidovudine

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-37

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.